Dementia Today.net

Site updated at Wednesday, 22 June 2016

Living with Dementia

Drug restores brain function and memory in early Alzheimer’s disease

  • - Dementia News
  • Mar 11, 2015
  • Comments
  • Viewed: 0
Tags: | alzheimer's disease | amnestic mild cognitive impairment | early alzheimer's disease | memory loss |

A novel therapeutic approach for an existing drug reverses a condition in elderly patients who are at high risk for dementia due to Alzheimer’s disease, researchers at Johns Hopkins University found.

The drug, commonly used to treat epilepsy, calms hyperactivity in the brain of patients with amnestic mild cognitive impairment (aMCI), a clinically recognized condition in which memory impairment is greater than expected for a person’s age and which greatly increases risk for Alzheimer’s dementia, according to the study published this week in NeuroImage: Clinical.

The findings validate the Johns Hopkins team’s initial conclusions, published three years ago in the journal Neuron. They also closely match the results in animal studies performed by the team and scientists elsewhere. Next, neuroscientist Michela Gallagher, the lead investigator, hopes the therapy will be tested in a large-scale, longer-term clinical trial.

Hippocampal over-activity is well-documented in patients with aMCI and its occurrence predicts further cognitive decline and progression to Alzheimer’s dementia, Gallagher said.

“What we’ve shown is that very low doses of the atypical antiepileptic levetiracetam reduces this over-activity,” Gallagher said. “At the same time, it improves memory performance on a task that depends on the hippocampus.”

The team studied 84 subjects; 17 of them were normal healthy participants and the rest had the symptoms of pre-dementia memory loss defined as aMCI. Everyone was over 55 years old, with an average age of about 70.

The subjects were given varying doses of the drug and also a placebo in a double-blind randomized trial. Researchers found low doses both improved memory performance and normalized the over-activity detected by functional magnetic resonance imaging that measures brain activity during a memory task. The ideal dosing found in this clinical study matched earlier preclinical studies in animal models.

“What we want to discover now, is whether treatment over a longer time will prevent further cognitive decline and delay or stop progression to Alzheimer’s dementia,” Gallagher said.

Other team members from Johns Hopkins included Arnold Bakker, assistant professor of psychiatry and behavioral sciences; Marilyn S. Albert, director of the Division of Cognitive Neuroscience in the Department of Neurology; professor of neurology Gregory Krauss and the clinical study coordinator, Caroline L. Speck.

Gallagher, the Krieger-Eisenhower Professor of Psychology and Neuroscience, is the founder of, and a member of the scientific board of, AgeneBio, a biotechnology company focused on developing treatments for diseases that affect brain function. The company is headquartered in Baltimore.

Gallagher owns AgeneBio stock, which is subject to certain restrictions under Johns Hopkins policy. She is entitled to shares of any royalties received by the university on sales of products related to her inventorship of intellectual property. The terms of these arrangements are managed by the university in accordance with its conflict-of-interest policies.

###

The team’s work was supported by National Institutes of Health grant RC2AG036419.

###

Jill Rosen
.(JavaScript must be enabled to view this email address)
443-997-9906

Johns Hopkins University

Journal
  NeuroImage

Post a comment [ + Comment here + ]

There are no comments for this entry yet. [ + Comment here + ]




Comment
Your details

* Required field


Please enter the word you see in the image below:

Comments are moderated by our editors, so there may be a delay between submission and publication of your comment. Offensive or abusive comments will not be published.

Living with dementia

diet high in carbohydrates1 - beta amyloid protein1 - amyloid plaque4 - memory losses1 - alzheimers disease25 - morosis1 - neurologic disorder1 - end-stage dementia1 - aggression or irritability1 - neurodegenerative disorder4 - amyloid protein1 - amyotrophic lateral sclerosis6 - korsakoff syndrome3 - anoea1 - dopamine-producing nerve cells1 - alzheimer's agitation1 - fibrous tangles1 - aids related dementia1 - ziveri1 - cognitive health3 - brain plaques1 - glucose hypometabolism1 - autism spectrum disorder1 - verbal fluency1 - fuller1 - pfizer1 - university of california2 - hormone therapy1 - senile atrophy and aphasia1 - margaret thatcher1 -